Audhya Paul K. — SEC Form 4 filings
SEC reporting owner CIK 1860131. 26 Form 4 filings on record with FilingPulse; latest filed 2026-06-11.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2024-02-13 to 2026-06-11. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 22 legs across 22 filings — 92,719 shares, $1,258,495 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 72.
- Largest priced transaction: sale of 14,295 shares @ $14.12 ($201,774) in KalVista Pharmaceuticals, Inc., filed 2024-02-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. (KALV) | CHIEF MEDICAL OFFICER | 26 | — | 22 legs · 92,719 sh · $1,258,495 | 72 |
Form 4 filings — Audhya Paul K.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-11 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Disposition to issuer (D): 150,260 @ $0 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 25,800 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 68,750 (derivative) · Disposition to issuer (D): 93,750 (derivative) | EDGAR |
| 2026-05-27 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 5,000 · Sale (S): 2,239 @ $26.78 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,250 · Sale (S): 2,685 @ $26.78 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-05-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 2,419 · Sale (S): 1,032 @ $26.76 · Option exercise (M): 2,419 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,250 · Sale (S): 2,686 @ $20.22 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2026-02-24 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,250 · Option exercise (M): 5,000 · Sale (S): 5,354 @ $15.57 · Option exercise (M): 6,250 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 2,419 · Sale (S): 1,163 @ $15 · Option exercise (M): 2,419 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-11-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,250 · Option exercise (M): 5,000 · Sale (S): 5,296 @ $13.45 · Option exercise (M): 6,250 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,447 · Sale (S): 3,075 @ $14.48 · Option exercise (M): 2,419 (derivative) @ $0 · Option exercise (M): 4,028 (derivative) @ $0 | EDGAR |
| 2025-08-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 5,000 · Sale (S): 2,336 @ $13.42 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-08-25 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,250 · Sale (S): 2,942 @ $13.22 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2025-08-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,446 · Sale (S): 2,939 @ $13.19 · Option exercise (M): 2,418 (derivative) @ $0 · Option exercise (M): 4,028 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 5,000 · Sale (S): 2,146 @ $11.31 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,250 · Sale (S): 2,689 @ $11.88 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,447 · Sale (S): 2,776 @ $11.84 · Option exercise (M): 2,419 (derivative) @ $0 · Option exercise (M): 4,028 (derivative) @ $0 | EDGAR |
| 2025-02-25 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 5,000 · Sale (S): 2,394 @ $10.02 · Grant/award (A): 100,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 6,447 · Sale (S): 3,125 @ $9.82 · Option exercise (M): 2,419 (derivative) @ $0 · Option exercise (M): 4,028 (derivative) @ $0 | EDGAR |
| 2024-11-27 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 5,000 · Sale (S): 2,187 @ $9.87 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-11-19 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 18,531 · Sale (S): 8,077 @ $9.26 · Option exercise (M): 2,419 (derivative) @ $0 · Option exercise (M): 4,028 (derivative) @ $0 · Option exercise (M): 12,084 (derivative) @ $0 | EDGAR |
| 2024-08-26 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 5,000 · Sale (S): 2,135 @ $12.40 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-08-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 18,528 · Sale (S): 7,973 @ $12.01 · Option exercise (M): 2,418 (derivative) @ $0 · Option exercise (M): 4,027 (derivative) @ $0 · Option exercise (M): 12,083 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 30,614 · Sale (S): 13,175 @ $11.76 · Option exercise (M): 2,419 (derivative) @ $0 · Option exercise (M): 4,028 (derivative) @ $0 · Option exercise (M): 12,084 (derivative) @ $0 · Option exercise (M): 12,083 (derivative) @ $0 | EDGAR |
| 2024-02-21 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Option exercise (M): 30,613 · Sale (S): 14,295 @ $14.12 · Option exercise (M): 2,419 (derivative) @ $0 · Option exercise (M): 4,028 (derivative) @ $0 · Option exercise (M): 12,083 (derivative) @ $0 · Option exercise (M): 12,083 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | KalVista Pharmaceuticals, Inc. (KALV) | Grant/award (A): 48,333 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1860131 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →